Avoiding obstacles when outsourcing your nonclinical research
Learn how to avoid obstacles when outsourcing your nonclinical research
In biopharmaceutical development, demonstrating efficacy and toxicity is a major milestone to entering human clinical trials. Most companies lack the internal resources to support all of their nonclinical development needs, relying on outsourcing some or all aspects of their program to nonclinical CROs. Knowing the technical challenges involved in outsourcing your program plays a critical role in bringing your drug to market and can mean the difference between meeting your next milestone on time or experiencing delays.
In this on-demand webinar, recorded on June 10th, 2020, Sinclair's Senior Vice President of Research, Scott E. Boley, PhD, DABT, shared insight on how to plan for obstacles drug developers will face in outsourcing nonclinical research and how to avoid critical missteps that can affect your program and timeline.
In this webinar you will learn:
- How clearly defined communications and protocols can avoid costly issues
- What to look for when selecting a nonclinical CRO
- How to get the most out of your pre-IND meeting
- What your CRO needs to know about your test article
About the Presenter:
Dr. Scott E. Boley, PhD, DABT, has advised Sponsors on their nonclinical needs for the last 15 years and managed toxicology programs for 19 years. He has extensive expertise in drug development as well as the regulatory expectations for a variety of test article types and indications. In his role as Senior Vice President of Research, Scott oversees the Research, Report Services, and SEND groups at Sinclair Research that supports each Sponsor’s nonclinical safety programs. Scott is a diplomate of the American Board of Toxicology and holds a B.Sc. in Biochemistry and a Ph.D. in Biochemistry/Environmental Toxicology from Michigan State University.